PE20160789A1 - Composiciones y metodos para admistracion de una enzima a las vias respiratorias de un sujeto - Google Patents

Composiciones y metodos para admistracion de una enzima a las vias respiratorias de un sujeto

Info

Publication number
PE20160789A1
PE20160789A1 PE2016000563A PE2016000563A PE20160789A1 PE 20160789 A1 PE20160789 A1 PE 20160789A1 PE 2016000563 A PE2016000563 A PE 2016000563A PE 2016000563 A PE2016000563 A PE 2016000563A PE 20160789 A1 PE20160789 A1 PE 20160789A1
Authority
PE
Peru
Prior art keywords
compositions
subject
methods
respiratory tract
enzyme
Prior art date
Application number
PE2016000563A
Other languages
English (en)
Spanish (es)
Inventor
Robert O Williams Iii
Steven Idell
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53005414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160789(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of PE20160789A1 publication Critical patent/PE20160789A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PE2016000563A 2013-11-04 2014-11-04 Composiciones y metodos para admistracion de una enzima a las vias respiratorias de un sujeto PE20160789A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361899739P 2013-11-04 2013-11-04

Publications (1)

Publication Number Publication Date
PE20160789A1 true PE20160789A1 (es) 2016-08-17

Family

ID=53005414

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000563A PE20160789A1 (es) 2013-11-04 2014-11-04 Composiciones y metodos para admistracion de una enzima a las vias respiratorias de un sujeto

Country Status (11)

Country Link
US (2) US20160279209A1 (enExample)
EP (1) EP3065705A4 (enExample)
JP (1) JP2016535782A (enExample)
KR (1) KR20160078986A (enExample)
CN (1) CN105764488A (enExample)
AU (1) AU2014341862A1 (enExample)
CA (1) CA2928759A1 (enExample)
CL (1) CL2016001062A1 (enExample)
MX (1) MX2016005720A (enExample)
PE (1) PE20160789A1 (enExample)
WO (1) WO2015066664A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4438044A3 (en) 2013-03-15 2024-12-04 Board of Regents, The University of Texas System Peptide fttftvt for use in treating fibrosis
AU2019339260B2 (en) 2018-09-10 2025-06-26 Rein Therapeutics, Inc. Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis
WO2021180068A1 (zh) * 2020-03-09 2021-09-16 泰伦基国际有限公司 一种治疗2019新型冠状病毒引发疾病的方法和药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4790305A (en) * 1986-06-23 1988-12-13 The Johns Hopkins University Medication delivery system
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US5302390A (en) 1987-07-01 1994-04-12 Beecham Group Plc Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
US5531219A (en) * 1994-11-04 1996-07-02 Alliance Pharmaceutical Corp. Use of liquid fluorocarbons to facilitate pulmonary drug delivery
WO1998006426A1 (en) * 1996-08-14 1998-02-19 Gram Joergen Brodersen Use of a plasminogen activator for the treatment of pulmonary disorders
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
CN1620334A (zh) * 2001-12-21 2005-05-25 环境清洁技术公司 锰氧化物的预处理与再生
US20050036951A1 (en) * 2003-01-09 2005-02-17 Arizeke Pharmaceuticals, Inc. Methods of treating lung diseases
US20050169908A1 (en) 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20060198940A1 (en) 2005-03-04 2006-09-07 Mcmorrow David Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance
US20070157931A1 (en) 2005-07-11 2007-07-12 Richard Parker System and method for optimized delivery of an aerosol to the respiratory tract
EP1962869B1 (en) * 2005-12-21 2013-03-20 SolAeroMed Inc. Treatment of respiratory diseases
SI22865A (sl) 2008-09-25 2010-03-31 Univerza@V@Ljubljani Peptid uroaktivin kot aktivator encima urokinaze
JP2012509941A (ja) * 2008-11-26 2012-04-26 ファイブ・プライム・セラピューティクス，インコーポレイテッド Ｓｅｒｐｉｎｅ２によるコラーゲンおよび平滑筋アクチンの発現を調節するための組成物および方法
DE102009031274A1 (de) * 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
WO2013029627A1 (en) * 2011-08-29 2013-03-07 Trifoilium Aps Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction

Also Published As

Publication number Publication date
US20190255157A1 (en) 2019-08-22
EP3065705A2 (en) 2016-09-14
CA2928759A1 (en) 2015-05-07
WO2015066664A2 (en) 2015-05-07
KR20160078986A (ko) 2016-07-05
AU2014341862A1 (en) 2016-05-19
CN105764488A (zh) 2016-07-13
US11033611B2 (en) 2021-06-15
MX2016005720A (es) 2016-11-25
CL2016001062A1 (es) 2017-01-13
US20160279209A1 (en) 2016-09-29
JP2016535782A (ja) 2016-11-17
WO2015066664A3 (en) 2015-09-17
EP3065705A4 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
JOP20130273B1 (ar) مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
MD20140134A2 (ro) Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
DOP2014000049A (es) Métodos para el tratamiento de hcv que comprenden al menos dos agentes antivirales de acción directa (daaas) y ribavirina pero no interferón
CR20150199A (es) Análogos de 2´-cloro nucleósido para infección por vhc
MX346861B (es) Metodos de tratamiento de carcinoma hepato celular.
MX2015009037A (es) Enjuague nasal con miel.
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
BR112017006113A2 (pt) combinações sinérgicas de auristatina
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2015011316A (es) Imidazopiridazinas sustituidas.
CL2015001742A1 (es) Unidad de filtro insertable para la insercion en un filtro de articulo de fumar que tiene un hueco, dicha unidad contiene un agente modificador de humo y ademas esta dispuesta para ser insertada en el hueco del filtro del articulo de fumar por un usuario; filtro.
CL2011000696A1 (es) Particulas inhalables que comprenden una forma anhidra amorfa de tiotropio con un agente estabilizante que es lactosa; composicion farmaceutica; procedimiento para prepararlas que incluye secado por atomizacion; y su uso en asma y epoc
BR112017018209A2 (pt) produtos terapêuticos de polipeptídeo e usos dos mesmos
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
MX381102B (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
PE20160789A1 (es) Composiciones y metodos para admistracion de una enzima a las vias respiratorias de un sujeto
BR112013003064A2 (pt) agente profilático ou terapêutico para a esteato-hepatite não alcoólica
AR076520A1 (es) Parasiticidas sanguineos. composicion
GEP20186863B (en) Pharmaceutical composition for use in increasing the trophism of nasal mucosa
BR112016017496A2 (pt) Composição para acelerar a penetração através da pele, preparação para administração transdérmica e preparação de emplastro de pele
DOP2013000182A (es) Inhibidores de catepsina c

Legal Events

Date Code Title Description
FD Application declared void or lapsed